Stock Ratings / Health Care / PRLD / insiders

TTRX (31) ENTA (25) ARCT (31) AVIR (40) ⌘ Pro Terminal →

Prelude Therapeutics Incorporated (PRLD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$4.10 -0.97% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.09

Prelude Therapeutics Incorporated (PRLD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $327.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.09 (-0.36%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRLD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY PRLD SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (24% of score)

FRED Regime × Technicals: 52% of 52W Range • RSI-14 at 49.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.89-16.2% Next Q

Q2 (-2Q)

Grade E$3.26+11.3% Next Q

Q3 (-1Q)

Grade E$3.63+12.9% Next Q

Current

Grade D-$4.10-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRLD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRLD currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.45) and Max Pain ($4.31) forces dealer call-delta covering toward $7.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRLD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRLD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PRLD Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PRLD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PRLD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRLD)

✓Walkthrough of PRLD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRLD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.61%📐 HORIZONTAL RANGE

2026-10-30O $4.02H $4.11L $3.82C $4.10VOL 217.5K

RES: $7.82SUP: $3.08SMA50: $4.45SMA200: $4.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRLD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRLD Butterfly Map → + Track PRLD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +73.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRLD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRLD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRLD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRLD)

Health Care Rank #610 of 1016 ⚔️ TTRX vs PRLD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRLD vs. TTRX, ENTA, ARCT, AVIR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prelude Therapeutics Incorporated (PRLD) ranks #610 by composite RQD confidence (41/100, grade D-) and #512 by equity capitalization ($327.2M). Within this direct 5-issuer industry benchmark cohort, PRLD leads on earnings valuation at N/A trailing P/E, while TTRX leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. PRLD currently leads its immediate peer cohort in composite quantitative strength at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRLD ACTIVE Prelude Therapeutics Incorporated	D-	41/100	—	—	-35.0%	-0.97%	$327.2M	Benchmark Subject
TTRX Turn Therapeutics Inc.	E	31/100	—	—	-28.3%	-3.60%	$327.3M	/ttrx-vs-prld →
ENTA Enanta Pharmaceuticals Inc.	E	25/100	—	—	-35.0%	-3.46%	$324.7M	/enta-vs-prld →
ARCT Arcturus Therapeutics Holdings Inc.	E	31/100	—	—	-35.0%	+0.66%	$345.3M	/arct-vs-prld →
AVIR Atea Pharmaceuticals Inc.	D-	40/100	—	—	-35.0%	+0.94%	$345.7M	/avir-vs-prld →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001678660

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prelude Therapeutics Incorporated (PRLD) reported GAAP revenue of $12.1M (+73.4% vs. FY2024 revenue of $7.0M ) , GAAP net income of -$99.5M, operating cash flow of -$56.3M, and free cash flow of -$56.4M (+45.6% YoY). On the balance sheet, PRLD closed FY2025 with $141.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$12.1M	-$99.5M	-$56.3M	-$56.4M	$141.3M	—
FY2024 (FY)	2024-12-31	$7.0M	-$127.2M	-$102.9M	-$103.7M	$175.5M	—
FY2023 (FY)	2023-12-31	$0	-$121.8M	-$107.1M	-$107.1M	—	—

3. PRLD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRLD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Prelude Therapeutics Incorporated (NASDAQ: PRLD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $4.10 (-0.97% 1D, market cap $327.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRLD ranks #610 in composite RQD confidence.

How does PRLD compare to TTRX and ENTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRLD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TTRX (Turn Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -28.3%, cap $327.3M) and ENTA (Enanta Pharmaceuticals Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $324.7M). Among the 5-stock peer group, PRLD leads on earnings multiple (N/A) while TTRX leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRLD?

Per PRLD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001678660), Prelude Therapeutics Incorporated generated $12.1M in revenue (+73.4% YoY), -$99.5M in net income, and -$56.4M in free cash flow against $141.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRLD trading relative to its 50-day, 200-day, and 52-week technical levels?

PRLD last traded at $4.10 (-0.97% on volume of 201,328 shares), positioning the stock -7.87% below its 50-day simple moving average ($4.45) and +2.24% above its 200-day simple moving average ($4.01). Across its 52-week range of $1.17 to $6.83, PRLD sits at the 51.8% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.59 to $4.61).

PRLD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PRLD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PRLD leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: PRLD RQD Cockpit PRLD 12M Forecast PRLD Earnings & Move PRLD Dividends & DRIP PRLD Insiders & 13F PRLD Whale Options PRLD Profit Sankey PRLD News & Why